CLINICAL_TRIALS
trial_result
· 2013-01-14
Clinical Trial Update: Safety and Dose Finding Trial of BM32 in Subjects Suffering From Grass Pollen Allergy [Phase 2]
Summary
Phase 2 safety and dose-finding study of BM32 in subjects with grass pollen allergy has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Biomay AG | Conditions: Grass Pollen Allergy | Phase 2 | Status: COMPLETED